Program
Rifampin
Also written as “Rifampicin”, “rifampicin” and “RSS0343 Tablet; Rifampicin Capsules”.
Its studies are mostly in Neoplasms · Tuberculosis, Pulmonary · Hematologic Neoplasms · Melanoma · Bronchiectasis, led by 28 companies.
Drug pageRifampin: every studyMany companies study it; this page follows only the 45 they lead. All 162 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 40 open or running | phase 1since Sep 25, 2007 | Sep 25, 2007 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 1since Aug 23, 2013 | Aug 23, 2013 | none ahead |
| HUTCHMEDits history only | 30 open or running | phase 1since Aug 10, 2020 | Aug 10, 2020 | none ahead |
| Jiangsu HengRui Medicineits history only | 32 open or running | phase 1since Jul 28, 2020 | Jul 28, 2020 | none ahead |
| Takedaits history only | 30 open or running | phase 1since Jan 23, 2008 | Jan 23, 2008 | none ahead |
| Boehringer Ingelheimits history only | 20 open or running | phase 1since Jun 20, 2014 | Jun 20, 2014 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 2since May 16, 2022 | Sep 26, 2013 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 1since Jan 9, 2013 | Jan 9, 2013 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 1since Jan 23, 2012 | Jan 23, 2012 | none ahead |
| Pfizerits history only | 20 open or running | phase 1since Oct 3, 2006 | Oct 3, 2006 | none ahead |
| PTC Therapeuticsits history only | 20 open or running | phase 1since Nov 4, 2014 | Nov 4, 2014 | none ahead |
| Bayerits history only | 10 open or running | phase 1since Nov 4, 2016 | Nov 4, 2016 | none ahead |
| Beijing Aosaikang Pharmaceuticalits history only | 10 open or running | phase 1since Nov 11, 2022 | Nov 11, 2022 | none ahead |
| Betta Pharmaceuticalsits history only | 11 open or running | phase 1since Jul 1, 2024 | Jul 1, 2024 | none ahead |
| Eisaiits history only | 10 open or running | phase 1since Jan 23, 2014 | Jan 23, 2014 | none ahead |
| Emalex Biosciencesits history only | 10 open or running | phase 1since Dec 22, 2023 | Dec 22, 2023 | none ahead |
| F2G Biotechits history only | 10 open or running | phase 1since Nov 19, 2019 | Nov 19, 2019 | none ahead |
| Guangdong Zhongsheng Pharmaceuticalits history only | 10 open or running | phase 1since Sep 4, 2023 | Sep 4, 2023 | none ahead |
| Idorsia Pharmaceuticalsits history only | 10 open or running | phase 1since Jul 5, 2018 | Jul 5, 2018 | none ahead |
| Ipsenits history only | 10 open or running | phase 1since Jul 29, 2020 | Jul 29, 2020 | none ahead |
| LG Chemits history only | 10 open or running | phase 1since Aug 31, 2011 | Aug 31, 2011 | none ahead |
| Phathom Pharmaceuticalsits history only | 10 open or running | phase 1since Sep 15, 2020 | Sep 15, 2020 | none ahead |
| SecuraBioits history only | 10 open or running | phase 1since Sep 18, 2013 | Sep 18, 2013 | none ahead |
| Sunshine Lake Pharmaits history only | 10 open or running | phase 1since Aug 31, 2021 | Aug 31, 2021 | none ahead |
| Thirty Respiratoryits history only | 10 open or running | phase 2since Aug 21, 2023 | Aug 21, 2023 | none ahead |
| TYK Medicinesits history only | 10 open or running | phase 1since Jan 17, 2024 | Jan 17, 2024 | none ahead |
| Vantiaits history only | 10 open or running | phase 1since May 7, 2015 | May 7, 2015 | none ahead |
| Vertex Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 19, 2009 | Nov 19, 2009 | none ahead |
Also a collaborator on its studies: Cambridge Cognition, Parexel, Covance and PRA Health Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 25, 2007First study: phase 1 study in NeoplasmsFirst studyNCT00534807 · United States
- Oct 26, 2009Phase 1 study in Alzheimer DiseaseNCT01002079 · 20 enrolled · India
- Mar 25, 2011Phase 1 study in Hematologic NeoplasmsNCT01324323 · 14 enrolled · United States, United Kingdom
- Feb 10, 2022Phase 1 study in Healthy AdultsNCT05255276 · 36 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 4 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05255276Healthy Adults · United States | 1 | Completed | May 12, 2022 | 36 |
| NCT01324323Hematologic Neoplasms · United States, United Kingdom | 1 | Completed | Feb 1, 2012 | 14 |
| NCT01002079Alzheimer Disease · India | 1 | Completed | Oct 2010 | 20 |
| NCT00534807Neoplasms · United States | 1 | Withdrawn | Nov 2008 | 0 |
How it is read
Names in the registry
- “Rifampin”, 18 entries
- “Rifampicin”, 9 entries
- “rifampicin”, 5 entries
- “RSS0343 Tablet; Rifampicin Capsules”, 1 entry
- “RIFAFOUR e-275”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 3 studies
- Tuberculosis, Pulmonary, 2 studies
- Hematologic Neoplasms, 2 studies
- Melanoma, 2 studies
- Bronchiectasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.